# Safety of a Single Dose of 5 mg of hLF1-11 Given to Autologous Haematopoietic Stem Cell Transplant Recipients

> **NCT00509938** · PHASE1,PHASE2 · COMPLETED · sponsor: **AM-Pharma** · enrollment: 8 (actual)

## Conditions studied

- Hematopoietic Stem Cell Transplantation
- Bacterial Infections and Mycoses

## Interventions

- **DRUG:** human lactoferrin peptide 1-11

## Key facts

- **NCT ID:** NCT00509938
- **Lead sponsor:** AM-Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-03
- **Primary completion:** 2006-11
- **Final completion:** 2006-11
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2008-10-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00509938

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00509938, "Safety of a Single Dose of 5 mg of hLF1-11 Given to Autologous Haematopoietic Stem Cell Transplant Recipients". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT00509938. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*